1. ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis .
- Author
-
Herricks T, Donczew M, Mast FD, Rustad T, Morrison R, Sterling TR, Sherman DR, and Aitchison JD
- Subjects
- Colony Count, Microbial, Humans, Kinetics, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis growth & development, Predictive Value of Tests, Reproducibility of Results, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology, Workflow, Antibiotics, Antitubercular pharmacology, Drug Resistance, Multiple, Bacterial genetics, Microbial Sensitivity Tests, Microscopy, Video, Mycobacterium tuberculosis drug effects, Ofloxacin pharmacology, Time-Lapse Imaging, Tuberculosis, Multidrug-Resistant diagnosis
- Abstract
Antimicrobial-resistant Mycobacterium tuberculosis (Mtb) causes over 200,000 deaths each year. Current assays of antimicrobial resistance need knowledge of mutations that confer drug resistance, or long periods of culture time to test growth under drug pressure. We present ODELAM (One-cell Doubling Evaluation of Living Arrays of Mycobacterium), a time-lapse microscopy-based method that observes individual cells growing into microcolonies. ODELAM enables rapid quantitative measures of growth kinetics in as little as 30 hrs under a wide variety of environmental conditions. We demonstrate ODELAM's utility by identifying ofloxacin resistance in cultured clinical isolates of Mtb and benchmark its performance with standard minimum inhibitory concentration (MIC) assays. ODELAM identified ofloxacin heteroresistance and the presence of drug resistant colony forming units (CFUs) at 1 per 1000 CFUs in as little as 48 hrs. ODELAM is a powerful new tool that can rapidly evaluate Mtb drug resistance in a laboratory setting., Competing Interests: TH, MD, FM, TR, RM, TS, DS, JA No competing interests declared, (© 2020, Herricks et al.)
- Published
- 2020
- Full Text
- View/download PDF